Celyad Oncology SA
CLYYF
$0.20
-$0.21-51.22%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.90K | 7.40K | 91.70K | 94.50K | 7.50K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.90K | 7.40K | 91.70K | 94.50K | 7.50K |
| Cost of Revenue | 4.50K | 4.20K | 1.60K | 1.60K | 4.80K |
| Gross Profit | 3.40K | 3.20K | 90.10K | 92.90K | 2.70K |
| SG&A Expenses | 952.80K | 883.40K | 778.70K | 803.10K | 934.80K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -55.00K | -51.00K | -108.70K | -112.10K | -99.60K |
| Total Operating Expenses | 2.08M | 1.93M | 1.58M | 1.63M | 1.67M |
| Operating Income | -2.07M | -1.92M | -1.48M | -1.53M | -1.66M |
| Income Before Tax | -2.09M | -1.93M | -1.48M | -1.53M | -1.64M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.09M | -1.93M | -1.48M | -1.53M | -1.64M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.09M | -1.93M | -1.48M | -1.53M | -1.64M |
| EBIT | -2.07M | -1.92M | -1.48M | -1.53M | -1.66M |
| EBITDA | -1.96M | -1.82M | -1.44M | -1.46M | -1.54M |
| EPS Basic | -0.05 | -0.05 | -0.04 | -0.04 | -0.04 |
| Normalized Basic EPS | -0.03 | -0.03 | -0.02 | -0.02 | -0.02 |
| EPS Diluted | -0.05 | -0.05 | -0.04 | -0.04 | -0.04 |
| Normalized Diluted EPS | -0.03 | -0.03 | -0.02 | -0.02 | -0.02 |
| Average Basic Shares Outstanding | 41.43M | 41.43M | 41.43M | 41.43M | 43.49M |
| Average Diluted Shares Outstanding | 41.43M | 41.43M | 41.43M | 41.43M | 43.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |